On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer’s ongoing focus on oncology and vaccines was emphasized, with significant investments in research and development. The company is also progressing with its cost restructuring program, aiming ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc ( (PFE) ), Astellas Pharma ( (ALPMF) ), Astellas Pharma ( (ALPMY)) announced an update on their ongoing clinical study.

Jim Cramer threw a curveball on Pfizer’s stock during a recent caller interaction, suggesting a wait-and-see approach ...

Genmab (Otc) (($GMAB)) announced an update on their ongoing clinical study. Pfizer Inc. and Genmab are conducting a Phase 4 ...

Pfizer has also ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer has also advanced its oncology clinical pipeline with several candidates entering late-stage ...

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...